James Brice

mailto:[email protected]

Good times ahead for MRI? Market conditions favor replacement

An era of constraint that compelled many MRI users to delay replacing their aging equipment may be coming to an end, and a new phase of scanner purchasing could be on the horizon, according to a new report on U.S. market conditions for the modality.

September 5, 2012

Radiologists vary DR image quality to optimize radiation dose

A new Chinese study questions the assumption that striving for the highest possible image quality is always the best approach. Researchers developed an x-ray optimization strategy that cuts the dose of digital radiography (DR) substantially by adjusting dose levels based on the type of exam being conducted.

August 23, 2012

Nuclear Medicine

New PET/CT facilities power utilization growth

The growing acceptance of PET/CT as an essential part of oncology services has helped increase its use in step with the hybrid modality's expanding installed base, according to a new report on PET/CT and PET market conditions.

August 20, 2012

Incidental findings on CT lung screening offer benefits, costs

Incidental findings uncovered at low-dose CT lung cancer screening increase the overall yield of malignancies diagnosed from the annual exams for high-risk, asymptomatic patients, but their evaluation adds an additional layer of cost to such programs, Danish researchers have found.

June 25, 2012

2012 06 25 15 42 37 817 Saghir Ct Lung Thumb

CT screening of COPD patients could boost cancer detection

Patients with chronic obstructive pulmonary disease (COPD) may carry a high enough risk for lung cancer to qualify them along with middle-aged smokers for annual low-dose CT lung cancer screenings -- even though they aren't covered under recently released guidelines.

June 18, 2012

CT's growth rate slows, but users remain optimistic

The growth rate for CT procedure volume has slowed markedly from the double-digit pace of a decade ago, but use of the modality is still growing, and CT users are generally optimistic, according to a new market research report from IMV Medical Information Division.

June 4, 2012

2012 06 01 14 51 07 866 Ct Procedure Volume Thumb

Survey finds Irish more positive on CT lung screening

A survey of patients with chronic obstructive pulmonary disease in the Republic of Ireland suggests that better access to healthcare and more firsthand experience with CT may explain why they expressed a greater willingness to undergo low-dose CT lung cancer screening than current and former smokers in the U.S.

May 29, 2012

ATS: Lung cancers arise from tissue damaged by emphysema

SAN FRANCISCO - Preliminary research from the University of Pittsburgh shows that lung cancers originate in areas of the lung damaged by emphysema. The finding, presented at this week's American Thoracic Society (ATS) meeting, adds to evidence suggesting that a common underlying mechanism links the two diseases.

May 23, 2012

Percutaneous cholecystostomy deemed safe for patients over 80

Patients in their 80s can tolerate percutaneous cholecystostomy, with or without subsequent surgery or related procedures, just as well as younger patients, according to a new report from the University of California, San Francisco and the San Francisco Veterans Affairs Medical Center.

April 24, 2012

Radiation Oncology/Therapy

Personalized dosimetry highlights Y-90 talks at SIR show

Radiation therapy with yttrium-90 (Y-90) microbeads is making strides, as witnessed by presentations at last month's Society of Interventional Radiology (SIR) meeting. Papers at the San Francisco meeting covered topics ranging from personalized dosimetry to just how close loved ones can get to patients who have received Y-90 therapy.

April 22, 2012

Page 2 of 7

$Guang-Yi Sun, MD, of the Chinese Academy of Medical Sciences in Beijing, China, discusses 10-year outcomes of hypofractionated radiotherapy in high-risk breast cancer.$

ASTRO: 10-year outcomes support hypofractionated radiotherapy in breast cancer

While hypofractionated radiotherapy is well established for whole-breast irradiation after breast-conserving surgery, there is little long-term data on its use post-mastectomy.

Astro 2026 Thumb 2

ASTRO: Few patients adhere to long-term hormone therapy after lumpectomy

Astro 2026 Thumb 2

ASTRO: Fractionated radiosurgery lessens brain metastases recurrence

ASTRO: Navigator program improves access for African American breast cancer patients

Free webinar for radiology leaders

Free webinar for radiology leaders

What are the effects of COVID-19 pneumonia after 5 years?

After five years, residual lesions persisted in 35.6% of survivors (37 of 104).

September 24, 2026

Representative longitudinal chest CT images and five-year parametric response mapping (PRM), pulmonary vascular CT reconstructions, and hyperpolarized xenon-129 (Xe-129) ventilation MRI scans from survivors of nonsevere and severe COVID-19 pneumonia. (A–F) Images in a 68-year-old male survivor of nonsevere COVID-19 pneumonia, (G–L) 62-year-old male survivor of severe COVID-19 pneumonia, and (M–R) 55-year-old male survivor of severe COVID-19 pneumonia. For each participant, the first three columns show coronal chest CT images from the acute phase (A, G, M), two-year follow-up (B, H, N), and five-year follow-up (C, I, O) (left to right). The fourth column (D, J, P) shows a coronal PRM image for each participant at five-year follow-up derived from paired inspiratory and expiratory CT scans, showing the spatial distribution of lung functional categories. Green indicates normal lung tissue, yellow indicates functional small airway disease, and red indicates emphysema. The second-to-last column shows volume-rendered small pulmonary vessel visualization (red) at five-year follow-up per participant (E, K, Q). The column on the far right (F, L, R) shows a hyperpolarized Xe-129 MRI ventilation defect percentage (VDP) map at five-year follow-up per participant. Dark blue represents high Xe-129 signal intensity, corresponding to well-ventilated lung regions, whereas red represents no Xe-129 signal intensity, corresponding to ventilation defects. At five-year follow-up, the 68-year-old survivor of nonsevere COVID-19 pneumonia (top row) showed near-complete radiologic resolution, no respiratory symptoms, and preserved pulmonary function. In contrast, the 62-year-old survivor of severe COVID-19 pneumonia (middle row) showed persistent fibrotic linear opacities without respiratory symptoms and mildly reduced pulmonary function. The 55-year-old survivor of severe COVID-19 pneumonia (bottom row) showed persistent scattered fibrotic linear opacities and focal emphysematous changes in both lungs, with dyspnea and impaired gas exchange function. The VDP values obtained from F, L, and R were 7.7%, 7.1%, and 6.3%, respectively.

USC researchers develop “plug-and-play" platform for PET tracers

Preliminary work suggests the approach can generate tracers targeting fibroblast activation protein.

September 24, 2026

Nuclear Medicine

Image-based grading system estimates nasopharyngeal carcinoma severity

By Amerigo Allegretto

The four-tier grading system showed excellent reliability and good prognostic value for patients with nasopharyngeal carcinoma.

September 23, 2026

Representative MRI scans for which the independently assigned imaging-derived extranodal extension (iENE) grades differed among the readers. (A) Axial and sagittal images in a 56-year-old male patient with nasopharyngeal carcinoma and cervical nodal metastases. Readers 1 and 3 interpreted the finding as a metastatic lymph node invading the left sternocleidomastoid muscle (arrow) and assessed an iENE grade of 3, whereas reader 2 assigned a grade of 2. After joint review, the radiologists reached a consensus on the absence of definite sternocleidomastoid muscle invasion, and the final iENE grade was 2. (B) Axial and sagittal images in a 52-year-old male patient with nasopharyngeal carcinoma and cervical nodal metastases. Reader 1 interpreted the findings as a single enlarged metastatic lymph node and assessed an iENE grade of 1, whereas readers 2 and 3 interpreted them as two coalescent metastatic lymph nodes (arrows) and assessed a grade of 2. After joint review, the radiologists reached a consensus on the coalescence of the two metastatic lymph nodes, and the final iENE grade was 2.

ASTRO 2026 to center on translating radiotherapy data into dialogue

Radiopharmaceutical therapy will feature in a dedicated hands-on workshop alongside a roundtable.

September 23, 2026

PACS workstations add to power consumption in radiology departments

By Amerigo Allegretto

PACS workstations consume about 25 kW when active while also consuming power cumulatively in powered down states.

September 23, 2026

Radiologist Dictating (1)

X-rays reveal severe aortic calcification in dialysis patients

The findings reinforce lateral lumbar radiography's potential as an accessible, low-cost tool for opportunistic cardiovascular risk stratification in dialysis care.

September 22, 2026

Podcast: OSHA report reveals more about 2023 MRI accident

By Amerigo Allegretto

MRI experts dive into Cal/OSHA's report on a 2023 MRI accident in which a nurse was pinned between an ICU bed and an MRI scanner.

September 22, 2026

The Invisible Force Podcast Album Cover

Ex-NFL QB Matt Hasselback points brain imaging study

The trial’s main goal it to establish methods for diagnosing chronic traumatic encephalopathy (CTE) in the living, rather that by postmortem exams.

September 21, 2026

Telix inks deal to acquire ITM for $1.65B

By Erik L. Ridley

The deal would create a combined company with significant radioisotope manufacturing, distribution, and radiopharmaceutical development capabilities.

September 21, 2026

Connectivity, wellness, education at center of SDMS annual meeting

By Amerigo Allegretto

Kevin Rooker outlines what attendees can expect at the 2026 SDMS annual meeting in Atlanta.

September 21, 2026

Georgia Atlanta Map Pin (1)

Better risk scoring could predict cirrhosis, HCC in patients with SLD

By Amerigo Allegretto

One proposed risk score, SAFE, showed modest benefit in patients with imaging-confirmed steatotic liver disease (SLD).

September 21, 2026

Liver Cancer 400

FES-PET guides second-line therapy decisions in breast cancer

FES-PET/CT results led to therapeutic management changes in 37.8% of patients.

September 18, 2026

Page 2 of 252